The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme as we advance to phase 3 trials. The plan is now to take CT-388 into a pair of phase 3 obesity studies this quarter, Roche confirmed today
doi: 10.7759/cureus.92454
One mechanism that reduces muscle mass involves activation of type II activin receptors, ActRIIA/B, which yield profound muscle growth in humans when blocked
The features that should prompt assessment are: Severe, sudden pain in the upper right or upper central abdomen Pain radiating to the right shoulder or to the centre of the back Pain that comes in episodes lasting 30 minutes to several hours, particularly after meals Persistent nausea or vomiting beyond the expected GLP-1 side-effect window Fever, chills, or feeling systemically unwell Yellowing of the skin or eyes (jaundice) Dark urine or pale stools The last three suggest more serious complications and warrant urgent medical review
Your GP or specialist weight management service can provide individualised guidance to optimise both safety and effectiveness of your treatment journey
On the other hand, Zepbound is a newer medication with a more advanced formulation